uniQure (NASDAQ: QURE) director trades options and shares on Form 4 filing
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
uniQure director Robert Gut reported option exercises and share sales in the company’s ordinary shares. On January 12, 2026, he exercised a stock option for 17,810 ordinary shares at $14.08 per share, converting derivative securities into directly held stock.
On the same date, he sold ordinary shares in several transactions: 17,310 shares at a weighted average price of $24.39 (with individual sale prices between $24.02 and $25.00), 500 shares at a weighted average price of $25.03 (with prices between $25.02 and $25.04), and 7,803 shares at $25.09. After these trades, he directly owned 32,342 ordinary shares. All transactions were carried out under a Rule 10b5-1 trading plan adopted on July 8, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 25,613 shares ($630,483)
Net Sell
5 txns
Insider
Gut Robert
Role
Director
Sold
25,613 shs ($630K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 17,810 | $0.00 | -- |
| Exercise | Ordinary Shares | 17,810 | $14.08 | $251K |
| Sale | Ordinary Shares | 17,310 | $24.39 | $422K |
| Sale | Ordinary Shares | 500 | $25.03 | $13K |
| Sale | Ordinary Shares | 7,803 | $25.09 | $196K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Ordinary Shares — 57,955 shares (Direct)
Footnotes (1)
- The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.02 to $25.00. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.02 to $25.04. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Stock Option vested in full on June 15, 2023.
FAQ
What options did Robert Gut exercise in uniQure (QURE)?
He exercised a stock option (right to buy) for 17,810 ordinary shares at an exercise price of $14.08 per share on January 12, 2026. The option had vested in full on June 15, 2023 and carried an expiration date of June 15, 2032.
Were Robert Gut’s uniQure (QURE) trades made under a Rule 10b5-1 plan?
Yes. The filing states that the transactions were effected under a sales plan adopted on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.